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In Brief
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cellular internalization via the targeting of
specific phospholipids followed by both
endocytosis and direct membrane
translocation.
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Cyclotides combine the stability of disulfide-rich pep-
tides with the intracellular accessibility of cell-pene-
trating peptides, giving them outstanding potential
as drug scaffolds with an ability to inhibit intracellular
protein-protein interactions. To realize and optimize
the application of cyclotides as a drug framework
and delivery system, we studied the ability of the pro-
totypic cyclotide, kalataB1, to entermammalian cells.
We show that kalata B1 can enter cells via both endo-
cytosis and direct membrane translocation. Both
pathways are initiated by targeting phosphatidyletha-
nolamine phospholipids at the cell surface and in-
ducing membrane curvature. This unusual approach
to initiate internalization might be harnessed to
deliver drugs into cells and, in particular, cancer cells,
whichpresent a higher proportion of surface-exposed
phosphatidylethanolamine phospholipids. Our find-
ings highlight the potential of these peptides as drug
leads for the modulation of traditionally ‘‘undrug-
gable’’ targets, such as intracellular protein-protein
interactions.
INTRODUCTION
Peptides are currently being investigated as potential leads for
drug development, and have the potential to be complementary
to or viable alternatives for small-molecule drugs or biologics
(Craik et al., 2013; Go´ngora-Benı´tez et al., 2014). Interest
in peptides as therapeutics has been driven not only by the
high potency and selectivity exhibited by stable disulfide-rich
peptides (e.g. conotoxin MVIIA, Prialt), but also by the discovery
of cell-penetrating peptides (CPPs): short, linear, cationic pep-
tidic sequences (e.g. TAT peptide) with the ability to breach
membrane barriers and deliver proteins into cells (Henriques
et al., 2006).
Cyclotides are a family of cyclic peptides isolated from
plants (Burman et al., 2014; Craik et al., 1999) with a unique
topology comprising a head-to-tail macrocycle and three in-
terlocking disulfide bonds, which together lend their structures
exceptional stability (Figure 1A) and resistance to proteolytic
degradation (Colgrave and Craik, 2004). Cyclotides haveChemistry & Biology 22, 1087–been categorized into the Mo¨bius, bracelet, and trypsin inhib-
itor subfamilies (Craik et al., 2004). Members of the Mo¨bius
and bracelet subfamilies can be found in the same plant
species (e.g. Oldenlandia affinis) and have similar structural
features and biological activities; in particular, they have
hydrophobic residues exposed at the surface, and possess
anti-HIV and toxic properties (Gustafson et al., 2004; Ireland
et al., 2008). Despite possessing identical topology to Mo¨bius
and bracelet cyclotides, members of the trypsin inhibitor sub-
family lack hydrophobic residues (Felizmenio-Quimio et al.,
2001), have exquisite trypsin inhibitory activity and low cyto-
toxicity (Hernandez et al., 2000), and have been found exclu-
sively in cucurbitaceous plant species (Mahatmanto et al.,
2015).
The application of cyclotides as drug leads (Henriques and
Craik, 2010; Jagadish and Camarero, 2010) was originally moti-
vated by their remarkable stability, diverse biological activities,
sequence variability, and amenability to chemical synthesis
(Daly et al., 1999; Tam and Lu, 1998). Numerous studies have
detailed the successful incorporation of linear bioactive peptides
grafted onto the cyclotide framework, resulting in improved sta-
bility while maintaining potency and selectivity for their targets
(Poth et al., 2013). In addition to rational design, high-throughput
screening approaches that build combinatorial libraries of cyclo-
tide analogs are being used for drug lead selection (Austin et al.,
2009; Getz et al., 2011, 2013).
Recent studies in which the cell-penetrating properties of
cyclotides were identified (Cascales et al., 2011; Contreras
et al., 2011; Greenwood et al., 2007) revealed that in addition
to being stable scaffolds, cyclotides have the potential to be
used to deliver bioactive peptides into cells, and thus target
intracellular proteins. This was recently confirmed in a study
wherein the cyclotide Momordica cochinchinensis trypsin inhib-
itor I (MCoTI-I), engineered to incorporate a peptide epitope that
mimics the N-terminal fragment of the intracellular protein p53,
displayed significant resistance to degradation in vivo (Ji et al.,
2013). The intracellular uptake of cyclotides belonging to the
trypsin inhibitor subfamily (i.e. MCoTI-I and MCoTI-II) is reported
to be dependent on endocytic routes (Cascales et al., 2011; Con-
treras et al., 2011; Greenwood et al., 2007) and independent of
insertion into the plasma membrane (Cascales et al., 2011;
D’Souza et al., 2014).
The activities reported for cyclotides belonging to the
Mo¨bius and bracelet subfamilies seem to broadly correlate
with binding to cell membranes (Henriques and Craik, 2012),
but little is known about their cell-penetrating properties or1097, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1087
Figure 1. Structural Properties of Cyclotides
(A) Three-dimensional structure (PDB: 1NB1, left) and sequence (right) of the
prototypic cyclotide, kB1. The knotted arrangement of the disulfide bonds is
shown in light gray andCys residues are labeled I to VI. The segments between
Cys are named loops 1–6.
(B) Surface structure representation of kB1 in two views. Left: The hydrophobic
residues (P3, V4, V10, W23, P24, and V25) of kB1 are exposed and form a
patch at the surface of the molecule. Residues that are important for mem-
brane binding localize to one side of the molecule, and include the residues in
the hydrophobic patch and also those in the so-called bioactive face (G6, E7,
T8, N15, T16, and R28). Right: Residues located in the ‘‘amendable’’ face (G1,
G18, T20, S22, T27, and N29) are delineated with a line. They are named
amendable because when replaced with a Lys residue they improve the
membrane-binding properties of the peptide (Henriques et al., 2011; Huang
et al., 2010).
See also Table S1.the mechanism by which they gain entry into cells. These cy-
clotides are known to target cells through interactions with
phospholipids containing phosphatidylethanolamine (PE) head-
groups in the plasma membrane, followed by insertion into
the lipid membrane through hydrophobic interactions (Henri-
ques et al., 2011, 2012, 2014; Wang et al., 2012). Furthermore,
when a threshold peptide concentration is reached at the
cell surface the plasma membrane integrity is compromised,
leading to membrane disruption followed by cell death (Henri-
ques et al., 2012; Huang et al., 2009). Nevertheless, studies
showing internalization of cyclotides without membrane per-
meabilization (Cascales et al., 2011) suggest that internalization
occurs at concentrations below those that cause membrane
disruption.
In this study we examined the cell-penetrating properties of
the prototypic cyclotide, kalata B1 (kB1), and elucidated the
importance of membrane-binding properties for its internaliza-
tion. This study reveals that kB1 is internalized as efficiently as
the gold standard CPP TAT, and shows that its uptake is depen-
dent on its ability to target cell membranes. These mechanistic
insights could assist in realizing the full potential of cyclotides
as drug scaffolds that can stabilize and deliver bioactive epi-
topes that modulate intracellular targets.1088 Chemistry & Biology 22, 1087–1097, August 20, 2015 ª2015 ElRESULTS
Internalization of Labeled kB1 Analogs
To investigate whether the specificity of kB1 for PE phospho-
lipids (Henriques and Craik, 2012; Henriques et al., 2011)
and its ability to bind to membranes play a role in its cell-
penetrating properties, four kB1 analogs including the mem-
brane-active [T20K]kB1 and the membrane-inactive [V25K]
kB1, [T16K]kB1, and [E7K]kB1 (Henriques et al., 2011) were
compared on their ability to enter human cells. The analogs
were labeled with a single Alexa Fluor 488 through amide
bond ligation at the side chain of the single Lys residue, allow-
ing labeling of the analogs on different faces of the kB1 surface
(Figure 1B; Table S1): [T20K]kB1 on the amendable face,
[V25K]kB1 on the hydrophobic face, and [T16K]kB1 and [E7K]
kB1 on the bioactive face. Hereafter, all kB1 mutants are
referred to by their mutation (e.g. T20K refers to [T20K]kB1),
and Alexa Fluor 488-labeled peptides are indicated by an
asterisk (e.g. T20K*). Notably, the labeled peptides all have
the same overall charge (i.e. zero) as native kB1. The label
has minimal effect on the overall hydrophobicity of the pep-
tides, as indicated by their retention times on high-performance
liquid chromatography (Table S1), and does not change the
membrane-binding properties or the bioactivity of kB1 analogs
(Henriques et al., 2011), as shown by surface plasmon reso-
nance (SPR) and toxicity studies (Figures S1A and S1B); hence,
T20K* can be used to examine cellular uptake of kB1 and the
importance of the specificity to PE phospholipids for its inter-
nalization, whereas V25K*, T16K*, and E7K* are membrane-
inactive analogs.
Internalization of kB1 mutants into HeLa cells, a cervical can-
cer cell line, was examined using flow cytometry (Figures 2A–2D)
in non-toxic and non-permeabilizing conditions (Figure S1C).
TAT was included as a positive control, and its derivative
TAT-G (in which positively charged residues are replaced with
Gly) (D’Souza et al., 2014), was included as a negative control
to evaluate non-specific cellular internalization. As each peptide
is labeled with Alexa Fluor 488 and its fluorescence emission
quantum yield is insensitive to environment (Gadd et al., 2012),
the mean fluorescence emission signal is directly proportional
to the amount of peptide internalized into cells, whereas the per-
centage of fluorescent cells represents the fraction of cells that
have internalized the peptide. The membrane-impermeable
dye trypan blue was added to quench the fluorescence of mem-
brane-bound peptide and/or of cells with compromised mem-
branes (Torcato et al., 2013).
We confirmed the ability of kB1 to be internalized by cells un-
der non-toxic and non-permeabilizing conditions (Figures 2A–
2C), as cells became fluorescent upon treatment with T20K*
and the percentage of fluorescent cells remains unchanged
after addition of trypan blue. A drop in the mean fluorescence
of T20K*-treated cells upon addition of trypan blue (Figure 2B)
suggests that a portion of peptide is cell membrane-bound and
is thus accessible to trypan blue (25%, as calculated from the
drop in the mean fluorescence). After 1 hr of treatment with
peptide, almost all of the cells (>90%) had internalized T20K*
(Figure 2A) and the amount of peptide internalized was uni-
formly distributed across the cell population (Figure 2C). The
amount of T20K* internalized is comparable with that of TAT*sevier Ltd All rights reserved
Figure 2. Internalization of kB1
(A–D) Internalization of labeled peptides into HeLa
cells was followed by mean fluorescence emission
intensity of Alexa Fluor 488 using flow cytometry
(excitation at 488 nm and emission at 530/30 nm).
Data points represent mean ± SD of three or more
experiments; 10,000 cells were screened per
sample.
(A) Percentage of fluorescent cells obtained upon
treatment with 4 mM TAT*, TAT-G*, T20K*, or
T16K* at 37C at different incubation times and
after addition of the non-permeable fluorescence
quencher trypan blue (160 mg/ml, n = 3).
(B) Mean cell fluorescence signal upon treatment
with 4 mMTAT*, TAT-G*, T20K*, or T16K* for 1 hr at
37C before and after addition of trypan blue (TB).
Data were normalized to the signal obtained with
T20K* after trypan blue (n = 6).
(C) Fluorescence histograms of HeLa cells ob-
tained after incubation with 4 mM TAT*, TAT-G*, or
T20K* for 1 hr at 37C and after addition of trypan
blue.
(D) Mean fluorescence signal of HeLa cells ob-
tained upon treatment with increasing concentra-
tions of T20K*, V25K*, E7K*, or T16K* for 1 hr at
37C and after addition of trypan blue (n = 3).
(E) Confocal live cell imaging micrographs ob-
tained with HeLa cells after incubation with 5 mM
T20K* or T16K* for 1 hr at 37C. 1024 3 1024
pixels; scale bar, 10 mm. The bar graph shows the
average cell fluorescence ± SD (n = 8 cells) in each
micrograph. Values are normalized to the average
of T20K*.
See also Figures S1 and S2.(Figure 2B), whereas membrane-inactive mutants (i.e. E7K*,
T16K*, and V25K*) have low internalization efficiency (Fig-
ure 2D), comparable with that of TAT-G* (Figures 2A and 2B).
The same trend was observed with other cell lines tested,
namely MM96L cells, a skin cancer cell line, and HFF-1, a
non-cancerous skin cell line (Figures S1D and S1E). Internaliza-
tion studies were conducted in either the absence or presence
of inactivated fetal bovine serum (10% v/v), and no significant
differences in the internalization of T20K* were detected
(Figure S1F).
Internalization of T20K*, T16K*, and V25K* into HeLa cells was
also examined using live cell imaging, which confirmed that
T20K* is internalized to a greater extent than T16K* (Figure 2E)
and V25K* (Figures S1G and S1H). The micrographs also
showed that T20K* is distributed within the cell with a punctate
pattern, which suggests that some peptide molecules localize
in vesicle-like compartments. Examination of the fluorescence
profile across the cell and comparison with the background fluo-
rescence suggests that some peptide might be diffusely distrib-
uted within the cytoplasm (Figure S1I).Chemistry & Biology 22, 1087–1097, August 20, 2015 ªQuantification of Internalized kB1
Monitored by Mass Spectrometry
To gather information on the fraction of
kB1 added extracellularly that can be
internalized by HeLa cells, a quantita-
tive methodology using multiple reaction
monitoring (MRM) was employed (Fig-ure S2A). Liquid chromatography (LC)-MRM analyses confirm
that kB1 can be detected inside cells in its oxidized form (Fig-
ure S2B). After incubation of HeLa cells in media containing
8 mM kB1, non-internalized peptide was washed off, and pep-
tide internalized and/or associated with cells was recovered
after cell disruption via sonication and solubilization with
acetonitrile and formic acid. The concentration of peptide de-
tected in a re-suspension of disrupted whole cells was 5.8 ±
2.4 mM, suggesting that a large proportion of the peptide
added to the growth medium can bind to the cell surface
and/or be internalized. To distinguish between peptide bound
to membranes and that inside cells, membrane-bound frac-
tions were separated from soluble fractions prior to quantita-
tion by LC-MRM (Figure S2A), where the concentrations of
kB1 were found to be 1.7 ± 0.7 and 1.7 ± 1.1 mM, respectively.
The similar values suggest that equal proportions of kB1 exist
within the cell in membrane-bound and non-membrane-asso-
ciated states. Overall, this suggests that a fraction of the pep-
tide introduced extracellularly to HeLa cells is bound to mem-
branes, whereas another fraction is able to cross membranes2015 Elsevier Ltd All rights reserved 1089
Figure 3. The Involvement of Endocytosis in
the Internalization of kB1 Mutants
(A) Internalizationof 4mMT20K* intoHeLacells after 1hr
incubation at 4C or at 37C in the absence/presence
of the endocytic inhibitors: Dynasore (80 mM), chlor-
promazine (CPZ; 10 mg/ml, 28 mM), 5-(N-ethyl-N-iso-
propyl)-amiloride (EIPA; 10 mM), methyl-b-cyclodextrin
(MbCD; 4 mM), and cytochalasin D (CytD; 20 mM), or
the combination of Dynasore with EIPA, MbCD, or
CytD. Internalization was followed by fluorescence
emission of Alexa Fluor 488 using flow cytometry
(excitation at 488 nm and emission at 530/30 nm).
10,000 cells were analyzed per sample and data points
represent mean ± SD. Data were normalized to
the mean fluorescence emission signal obtained with
4 mM T20K* after treatment with trypan blue (n = 6).
Statistical analysiswas performedby one-way ANOVA,
with Bonferroni test (**p < 0.01, ***p < 0.001, ****p <
0.0001).
(B and C) Mean fluorescence emission (excitation
488 nm, emission 530/30 nm) of HeLa cells incubated
at 37C at various incubation times with (B) 4 mM T20K* without/with 30 min pre-treatment with 50 mM Myr-PI, and (C) with 4 mM T20K-pHrodo without/with
30 min pre-treatment with 80 mMDynasore or with 50 mMMyr-PI. Data points represent mean ± SD of three experiments, and were normalized to the average at
60 min without inhibitor; 10,000 cells were analyzed per sample.
(D) Confocal live cell imaging micrographs obtained with HeLa cells upon incubation with 10 mM T20K-pHrodo at 37C. 2048 3 2048 pixels; scale bar, 10 mm.
The plot shows the average cell fluorescence integrated density (n = 9) ± SEM within the image field over time. Fluorescence integrated density was calculated
using ImageJ.
(E) SPR sensorgrams obtained upon injection of 64 mM kB1 over POPC/POPE (4:1) bilayers either in buffer at pH 7.4 (10 mM HEPES buffer containing 150 mM
NaCl) to mimic membrane-binding properties in the extracellular and cytoplasmic pH, or in buffer at pH 5.5 (20 mM sodium acetate buffer containing 150 mM
NaCl) to examine membrane-binding affinity in the endosome compartment environment.
See also Figures S3 and S4.and localize either in the cytoplasm or within endosome
compartments.
The Role of Endocytosis for kB1 Internalization
To evaluate the potential role of endocytic pathways in the inter-
nalization of kB1 into HeLa, cellular uptake of T20K* was fol-
lowed either at 4C or after pre-treatment with a range of endo-
cytic inhibitors at 37C. Specifically, we used chlorpromazine
(CPZ) to inhibit the clathrin-mediated pathway, 5-(N-ethyl-N-iso-
propyl)-amiloride (EIPA) to inhibit macropinocytosis, andmethyl-
b-cyclodextrin (MbCD) to inhibit lipid raft/caveolae-dependent
endocytosis. In addition to the specific inhibitors, treatment
with Dynasore and cytochalasin D (CytD) were also tested to
assess dependence on dynamin and actin, respectively. Condi-
tions and concentrations for each inhibitor have been previously
established for HeLa cells (Chao and Raines, 2011; Duchardt
et al., 2007).
Studies conducted at 4C revealed that internalization of
T20K* is inhibited at this temperature (Figure 3A) but can be
restoredwhen the temperature is increased to 37C (Figure S3A).
Decreased internalization at 4C might result from inhibition of
ATP-dependent processes, such as endocytosis, and/or from
a decrease in membrane dynamics due to reduced fluidity of
the lipid bilayer.
Treatment with the specific endocytic inhibitors EIPA, MbCD,
and CPZ had no effect on the overall uptake of T20K*. Treatment
with Dynasore or CytD, on the other hand, decreased the inter-
nalization efficiency by 34% (Figure 3A). To examine if inhibition
of a specific endocytic pathway activates others, we evaluated
the effect of treating the cells with Dynasore combined with
EIPA, MbCD, or CytD. The combination of Dynasore with EIPA1090 Chemistry & Biology 22, 1087–1097, August 20, 2015 ª2015 Elor MbCD did not result in a further decrease in internalization
compared with treatment with Dynasore alone. The combination
of CytD and Dynasore decreased internalization by 44% when
compared with conditions without the inhibitor. These results
suggest that the uptake mechanism in HeLa cells is independent
of a specific endocytic pathway but partially dependent on both
dynamin and actin.
To confirm whether the reduced internalization of T20K* into
HeLa cells induced by Dynasore results from the role of dynamin
in clathrin-dependent endocytosis, we used a dynamin inhibitory
peptide (Myr-PI; myristoylated QVPSRPNARAP). This peptide is
able to get into cells (Nong et al., 2003) and in doing so prevents
the binding of dynamin to the adaptor protein amphiphysin,
thereby preventing clathrin-dependent endocytosis by inter-
fering with the formation of clathrin/dynamin complex and scis-
sion of vesicles (Grabs et al., 1997; Linden, 2012). Surprisingly,
instead of inhibiting, treatment of cells with Myr-PI increased
the internalization rate of T20K* by 3-fold at 37C (Figure 3B)
compared with non-treated cells, but had no effect on the
internalization of TAT* or TAT-G* (Figure S3B). This effect in
T20K*, but not in other peptides, suggests that Myr-PI modifies
cell membrane properties in a way that specifically facilitates
internalization of T20K* without making the membrane more
permeable to other peptides, and suggests that T20K* can be
internalized by a mechanism independent of endocytosis. This
hypothesis is further supported by the 13-fold increase in the
internalization rate of T20K* at 4C after pre-treatment with
Myr-PI at 37C (Figure S3C) compared with non-treated cells.
As acidification of endocytic compartments is a hallmark
of endocytosis, the potential involvement of an endosomal
pathway was further evaluated through treatment of cells withsevier Ltd All rights reserved
T20K labeled with pHrodo green, a dye that is non-fluorescent at
physiological pH but exhibits an increase in fluorescence quan-
tum yield at acidic pH (Miksa et al., 2009). Therefore, cells
become fluorescent if the peptide internalizes into endocytic
compartments, whereas peptide located in the cytoplasm has
very weak fluorescence. Flow cytometry showed an increase
in the fluorescence signal of T20K-pHrodo-treated cells with
time (Figure 3C). This was also confirmed by live cell imaging
with confocal microscopy (Figure 3D); initially the sample
was non-fluorescent upon addition of T20K-pHrodo but cells
become fluorescent over time, suggesting internalization of
T20K-pHrodo into acidic compartments. Treatment of cells
with Dynasore reduced the fluorescence signal (Figure 3C),
which might result from a slower internalization rate and/or less
peptide migrating toward more acidic compartments. These re-
sults confirm that internalization of T20K into HeLa cells is, at
least partially, dependent on endocytosis and dynamin. Interest-
ingly, treatment of cells with Myr-PI decreased the fluorescence
of cells incubated with T20K-pHrodo (Figure 3C), opposite to the
effect observed in the fluorescence of cells incubated with T20K*
(Figure 3B). This result suggests that treatment with Myr-PI im-
proves the overall internalization of T20K, as measured with
T20K*, but reduces its internalization and progression toward
the endocytic pathway, as followed with T20K-pHrodo. The pro-
gression of kB1 into endosomes is not modulated by any effect
of pH onmembrane-binding affinity as tested by SPR (Figure 3E);
therefore, we do not anticipate a preference for acidic over
neutral pH environments.
The Influence of PE Phospholipids and Membrane
Fluidity on the Ability of kB1 to Translocate Membranes
Biophysical studies using model membranes were conducted to
examine whether kB1 can translocate through lipid membranes.
Biological membranes have asymmetric lipid distributions and
commonly have a low proportion of PE exposed in the outer
leaflet (e.g.5%) (Daleke, 2008); nevertheless, this small propor-
tion of PE has been shown to be enough to promote binding of
kB1 to both model membranes and biological cells (Henriques
et al., 2011, 2014). In the current study, model membranes
with or without 20% of PE phospholipids were compared to
examine the potential role of PE phospholipids in the activity of
kB1. This higher proportion of PE incorporated within model
membranes, relative to levels in the outer leaflet of mammalian
cells, was required to allow detection and quantification of the
effects induced by kB1.
Giant vesicles (GVs) composed of palmitoyloleoylphosphati-
dylcholine (POPC) or POPC/palmitoyloleoylphosphatidyletha-
nolamine (POPE) were incubated with kB1 and observed using
confocal microscopy to evaluate effects of the peptide on mem-
brane stability (Figure 4A). kB1 was found not to induce visible
effects on POPC membranes, but induced budding and invagi-
nation in POPC/POPEmembranes. As evident in GVs with multi-
lamellae (panel 3 in Figure 4A), kB1 has the ability to translocate
through the outer bilayer, and bind to and induce the same invag-
ination in the inner lamella. The membrane-inactive mutant T16K
did not induce visible effects on either POPC (data not shown) or
POPC/POPE GVs (panel 4 in Figure 4A).
Previous studies suggested that in addition to specificity for
PE phospholipids, membrane fluidity also affects the ability ofChemistry & Biology 22, 1087–kB1 to bind to model membranes (Henriques et al., 2012). We
examined the effect of membrane fluidity upon the membrane-
binding affinity of kB1 by exposing it at 25C to lipid mixtures
containing 20%of PE phospholipids within POPC or dipalmitoyl-
phosphatidylcholine (DPPC) matrices, which respectively mimic
membranes in lamellar fluid-phase and lamellar solid-phase
environments. The role of the PE-phospholipid acyl chain was
also examined by comparing the PE-containing phospholipids:
dioleoylphosphatidylethanolamine (DOPE), POPE, dimyristoyl-
phosphatidylethanolamine (DMPE), and dipalmitoylphosphati-
dylethanolamine (DPPE) (Figures 4B and 4C). kB1 has a higher
affinity for PE-containing membranes with POPC than those
containing the DPPC matrix, confirming a preference for mem-
branes in the fluid phase. These results support the hypothesis
that in addition to PE targeting, kB1 relies upon hydrophobic in-
teractions to elicit efficient targeting of, and insertion into, the
membrane (Henriques et al., 2011, 2012; Wang et al., 2012).
We found that PE-phospholipid acyl chains also influence the af-
finity of kB1 for the membrane, which is inversely proportional to
the transition temperature of the individual lipids as follows:
DPPE < DMPE < POPE < DOPE (Figures 4B and 4C). This is
the same order as the tendency of the PE phospholipids to tran-
sition from lamellar fluid phase to hexagonal phase, which can be
an indication of non-lamellar events being involved in the trans-
location of kB1 through the lipid membrane.
The formation of hexagonal-phase and negative membrane
curvature has been suggested as an intermediate step in the
internalization of other CPPs (Mishra et al., 2011). Thus, to
examine whether kB1 can induce hexagonal-phase formation,
static 31P solid-state nuclear magnetic resonance (NMR) spec-
troscopy was conducted using POPC/DOPE membranes. The
typical spectrum profile observed with phospholipids organized
in lamellar bilayers has an asymmetrical line shape and is twice
the width of that observed for phospholipids organized in hexag-
onal phase. We found that the static 31P spectrum of POPC/
DOPE membranes in the absence of kB1 showed a pattern
typical of lipid bilayers in a fluid lamellar phase (Figure 4D, upper
panel). In the presence of kB1 (peptide-to-lipid ratio [P/L] 1:10),
there was a significant reduction in the overall chemical shift
anisotropy and the formation of isotropic peaks (centered at
0 ppm), but no evidence for hexagonal-phase formation. A
reduction in the chemical shift anisotropy suggests that phos-
phate groups aremore disordered, whereas isotropic orientation
indicates that kB1 induces fast tumbling of lipids, which could
result from lateral diffusion of lipids in highly curved membrane
domains.
To evaluate the effect of kB1 on the individual lipids, the 31P
isotropic chemical shifts of POPC and DOPE were resolved
by high-resolution magical angle spinning (MAS) (Figure 4D,
lower panel). Comparison of MAS spectra in the presence and
absence of kB1 showed a downfield shift of 0.16 ppm in the
resonance of DOPE induced by kB1, whereas the resonance
of POPC shifted by only 0.06 ppm (Table S2). Interestingly, the
deconvoluted spectra showed that kB1 induced the formation
of a third component centered at 0.20 ppm, which contributed
to 15% of the overall spectrum. This is indicative of a peptide-
bound population in slow exchange (Bechinger, 2005). These
results confirm the ability of kB1 to bind to membranes, and sug-
gest that kB1 has a higher affinity for DOPE lipids than POPC.1097, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1091
Figure 4. Effect of kB1 on Lipid Membranes and the Role of PE Phospholipids
(A) GVs labeledwith 1%NBD-PE visualized by confocalmicroscopy after incubationwith peptide (15min): 1, POPCwith 10 mMkB1 (5123 512 pixels); 2, 3, POPC/
POPE (4:1) with 5 mM kB1; 4, POPC/POPE (4:1) with 10 mM T16K (scale bar 10 mm; micrograph size is 512 3 512 pixels for 1, 2 and 4; 2413 241 pixels for 3).
(B) SPR sensorgram obtained upon injection of 40 mM kB1 over POPC or DPPC bilayers containing 20% of DPPE, DMPE, POPE, or DOPE deposited over an L1
chip surface. kB1 was injected for 180 s and dissociation followed for 600 s. Response units were converted into peptide-to-lipid ratio (P/L; mol/mol) to normalize
the response to the amount of peptide as before (Henriques et al., 2011).
(C) P/L at the end of peptide injection plotted versus peptide concentration.
(D) Static (upper) and MAS (lower) 31P NMR spectra of POPC/DOPE (1:1) MLV without (black) and with (gray) kB1 at P/L 1:10. Insets show deconvolution of the
MAS spectra using Lorentzian functions and their sum (dashed lines). Experiments were performed at 30C.
(E) Pake (upper) and dePaked (lower) 2H NMR spectra of POPC/d31-POPC/DOPE (1:1:2) without (black) and with (gray) kB1 at P/L 1:10.
See also Table S2.To gain more information on the perturbation of themembrane
hydrophobic core, 2H NMR studies were conducted with deuter-
ated POPC (d31-POPC) in POPC/DOPE mixtures (Figure 4E;
Table S2). The deuterium quadrupolar splitting near the glycerol
backbone (C2 to C6, see CD2 values in Table S2) were slightly
reduced while the methyl deuterons (C16, see CD3 values)
were unaffected by the presence of kB1, indicating a preference
for the membrane interface region, rather than a deep insertion
into the hydrophobic core of the bilayer. As observed in the 31P
NMR experiments, a small isotropic peak is present at 0 kHz,
supporting the presence of a fast tumbling population that in-
volves the headgroups and the acyl chains.1092 Chemistry & Biology 22, 1087–1097, August 20, 2015 ª2015 ElDISCUSSION
The goal of this study was to determine the mechanism by which
kB1 enters cells. Wewere particularly interested in evaluating the
contribution of membrane binding toward cell entry, and then
distinguishing between the internalization processes of endocy-
tosis and direct translocation through the plasma membrane.
Our results suggest that kB1 can enter cells via both endocytosis
and direct translocation, but binding to cell membranes appears
to be the first step for both mechanisms.
We confirmed that kB1 can internalize via non-toxic and non-
permeabilizingmechanisms (Figure S1C) and to an extent similarsevier Ltd All rights reserved
to that of TAT (Figure 2), the gold standard CPP. Internalization of
kB1 was confirmed both when conjugated to fluorescent dyes
and as an unlabeled peptide. Using MRM it was possible to
quantify the amount of peptide associated with cells, and to
distinguish between peptide associated with membranes and
peptide in solution inside cells. The significant proportions of
kB1 found to have been internalized by HeLa cells (>20% of
that present in media) suggests that therapeutic concentrations
of designed peptide drugs based on cyclotide scaffolds can in
principle be delivered to intracellular targets.
Our mechanistic studies show that the overall uptake of kB1 is
potentiated by its ability to bind to cell membranes by targeting
PE phospholipids (Henriques et al., 2011) and is, at least partially,
dependent on endocytosis. The importance of membrane-bind-
ing properties to uptake efficiency is revealed by the markedly
reduced extent of internalization for membrane-inactive com-
pared with membrane-active kB1 analogs. T16K*, with the
same mass, type of mutation, and overall structure as T20K*
(Huang et al., 2010), is unable to bind membranes (Figure S1A;
Henriques et al., 2011) and has a significantly lower internaliza-
tion rate than T20K* in all cell lines tested (Figures 2, S1D, and
S1E). As T20K* and T16K* only differ in their ability to bind PE
phospholipids, the distinctive internalization efficiency is prob-
ably dependent on the ability of T20K* to target and insert
into PE-containing membranes. The potential contribution of
PE phospholipids in the internalization of kB1 is further sup-
ported by studies with annexin V, a protein shown to bind PE
phospholipids exposed on the membrane (Marconescu and
Thorpe, 2008). The presence of annexin V decreased the inter-
nalization of T20K* but did not affect the internalization of TAT*
(Figure S3D).
The importance of endocytosis is supported by our work with
T20K-pHrodo, which demonstrates internalization of kB1 into
acidic compartments, and with endocytic inhibitors revealing
that internalization into HeLa cells is partially dependent on dy-
namin and actin. Dynamin is a large GTPase involved in the
budding and scission of nascent vesicles from the plasmamem-
brane, and can be involved in clathrin- and caveolae-dependent
endocytosis. As neither CPZ nor MbCD treatment impaired kB1
internalization, cell entry is unlikely to occur specifically by cla-
thrin- or caveolae-dependent processes. Actin is important for
cell motility and is involved in macropinocytosis, but treatment
with EIPA, an inhibitor of macropinocytosis, did not decrease
kB1 uptake; therefore, we excluded macropinocytosis as a spe-
cific internalization route used by kB1. The dynamin-actin com-
plex has been suggested to have a central role inmany important
motile functions within the cell (Orth and McNiven, 2003). There-
fore, the drop in kB1 uptake in HeLa cells treated with Dynasore
and/or CytD might result from effects on the cytoskeleton and
motile functions within the cell. According to this hypothesis,
kB1 could enter cells by a multi-endocytic mechanism, and its
internalization would be impaired by inhibition of dynamin- and
actin-mediated motile functions.
Despite its ability to induce local disturbances in the lipid
bilayer (Figure 4; Henriques et al., 2011), kB1 does not seem to
interfere with a cell’s overall endocytic activity, uptake of phos-
pholipids, or cell membrane integrity (Figures S3E and S3F).
The assembly of the endocytic machinery is restricted to the in-
ner leaflet of the plasma membrane (Godlee and Kaksonen,Chemistry & Biology 22, 1087–2013); therefore, we propose that kB1 is internalized by endocy-
tosis when bound to regions with existing endocytic machinery.
Such amechanism has been demonstrated for other cargos able
to internalize after diffusion into pre-formed endocytic sites
(Godlee and Kaksonen, 2013). As internalization of kB1 into
HeLa cells was not totally abolished upon treatment with endo-
cytic inhibitors administered either individually or in combination,
an alternative process independent of ATP might also be active.
Our studies with model membranes revealed that kB1 is able
to promote vesicle budding and translocate through pure lipid
bilayers containing PE phospholipids. Model membranes are
characterized by symmetrical lipid composition between leaf-
lets, but the generation of membrane curvature, as observed
with kB1 in GVs, can only be explained when membrane asym-
metry is generated (Graham and Kozlov, 2010). Membrane
asymmetry andmembrane bending can occur by direct insertion
of hydrophobic domains of peptides/proteins into one of the
leaflets by generating local curvature if the peptide inserts near
the surface, or by expanding the total area of one monolayer,
in respect to the other layer, if the peptide spans through the
monolayer (Graham and Kozlov, 2010). Our SPR results suggest
that kB1 inserts into the membrane rather than simply being ad-
sorbed at the surface, and solid-state NMR showed that the
insertion occurs within the headgroup region rather than the hy-
drophobic core. Together, these results support the notion that
kB1 inserts into the outer leaflet instead of spanning the lipid
bilayer, and creates the membrane asymmetry required to pro-
mote membrane bending. From a physical point of view, mem-
brane bending requires energy, but insertion of peptides into
lipid bilayers has been shown to be sufficient to meet the
required energy demands of inducing such curvature (Simunovic
and Bassereau, 2014). Thus, the ability of kB1 to induce bilayer
bending and translocate through lipid bilayers is also probably
operative in cell membranes. Previous studies suggest that
kB1 is able to induce outward transbilayer movement of PE
phospholipids and self-promotes its binding to the membrane
by increasing the amount of PE in the outer layer (Henriques
et al., 2011). A fraction as low as 0.1% of phospholipids being
transferred between the two leaflets can promote vesicular
structures in GVs (Farge and Devaux, 1992); therefore, upon
binding to the cell membrane, kB1 might induce local effects
on the plasma membrane and self-promote its internalization.
An increase in the internalization of kB1 in the presence ofMyr-
PI, both at 4C and 37C, cannot be explained by an increase in
transport via endocytic pathways. Direct membrane transloca-
tion could explain why treatment with Myr-PI increased the over-
all internalization rate of kB1 into HeLa cells but decreased the
internalization/progression through endocytic pathways. Amphi-
physin is a protein that inserts into the cytosolic leaflet, and in-
duces the membrane curvature required for the recruitment of
clathrin and dynamin for vesicle formation and scission of endo-
somes from the cell membrane (McMahon and Boucrot, 2011).
Myr-PI inhibits the binding of amphiphysin to dynamin required
for the scission of clathrin-coated vesicles (Grabs et al., 1997;
Linden, 2012), and as a consequence there is an accumulation
of highly curved regions in the cell membrane. Our hypothesis
is that regions with high inner curvature might expose more
PE phospholipids, assist membrane binding, and accelerate
membrane translocation of kB1, while decreasing the amount1097, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1093
Figure 5. Model of the Mechanism of Internalization of kB1
(1) Targeting of the cell membrane through PE phospholipids increases the
concentration of kB1 in themembrane vicinity; (2) insertion into the outer leaflet
induces a local increase of kB1molecules andmembrane disturbances, which
lead to (3) internalization through (i) endocytosis or (ii) internalization by an
energy-independent process, whereby the ability to insert and induce tum-
bling of phospholipids and vesicle-like formation is important for the peptide to
cross the lipid bilayer. The bioactive face and the hydrophobic patch are
shown in dark and light gray, respectively.of peptide available to internalize via endocytosis. This would
also explain the 13-fold increase in the internalization of T20K*,
but not T16K*, at 4C upon pre-treatment with Myr-PI. Studies
conducted with MM96L cells (Figures S1D and S4) further sup-
port this hypothesis and suggest that the endocytic pathway(s)
by which kB1 is internalized is dependent on the cell type (e.g.
treatment with CPZ induced a significant decrease in the inter-
nalization of T20K* into MM96L but not into HeLa; see Figures
3 and S4).
The internalization mechanism of kB1 proposed here is repre-
sented in Figure 5 and can be summarized as follows: the pep-
tide targets the cell membrane through binding of the bioactive
patch to PE headgroups exposed at the cell surface (step 1).
This is followed by insertion into the outer membrane layer
through hydrophobic interactions between the hydrophobic
face of the peptide and the phospholipids (Henriques et al.,
2011) (step 2). When the peptide accumulates in regions where
endocytic machinery is in place, it is internalized following
multi-endocytic pathways (step 3-i); actin and dynamin are prob-
ably involved in the subsequent motile functions. Alternatively,
when a sufficient number of peptides is bound to the outer leaflet
of the bilayer, local membrane bending occurs and the peptide
internalizes by direct translocation through the plasma mem-
brane (step 3-ii).
Based on our biophysical studies on model membranes, we
hypothesize that translocation through the membrane might
occur due to the formation of a non-bilayer intermediate in which
the peptide molecules are in a peptide-lipid complex with PE
phospholipids. Upon recovery of the lipid bilayer structure, the
peptide molecules can be distributed on both sides of the
bilayer, in a manner similar to that previously proposed for anti-
microbial peptides (Powers et al., 2005). After this step themem-
brane regains integrity and re-forms a permeability barrier. The
existence of a dynamic process whereby peptides and lipids
are continually being redistributed between leaflets is also in1094 Chemistry & Biology 22, 1087–1097, August 20, 2015 ª2015 Elagreement with previous observations that kB1 induces transbi-
layer movement of phospholipids in non-permeabilizing condi-
tions, and with its ability to induce echinocyte formation in red
blood cells (Henriques et al., 2011). High peptide concentrations
can lead to extrememembrane deformation, leakage of cell con-
tents, and induction of cell death (Henriques et al., 2014).
Conventional linear positively charged CPPs (e.g. TAT and R9)
have a high Arg/Lys content. A single model cannot explain
the internalization mechanism used by all CPPs, and indeed
consensus is hard to achieve even for a single CPP. Overall,
the way CPPs obtain access to the cell seems to depend on
the peptide itself, experimental conditions, cargo, and cell type
(Duchardt et al., 2007), but there is an increasing body of evi-
dence suggesting that their positive charges are essential in
increasing their concentration at the cell surface and in inducing
cellular uptake. The fact that kB1 is internalized through targeting
of PE phospholipids with subsequent insertion into the cell mem-
brane is interesting, and indicates that cyclotides might have
evolved a novel strategy to enter cells. Although other cyclotides
belonging to the Mo¨bius or bracelet subfamilies were not in-
cluded in this study, we hypothesize that other native cyclotides
that also are able to specifically bind PE phospholipids (Henri-
ques et al., 2012) should be able to internalize inside cells at
non-toxic and non-permeabilizing concentrations.
Cyclotides and other knotted peptides have been explored as
potential drug scaffolds. It has been shown that the uptake
mechanism of a given CPP affects the location and determines
the bioactivity of the cargo (Duchardt et al., 2007); therefore, to
enable the wider application of the cyclotide framework for deliv-
ery to intracellular targets, it is important to understand their
mode of uptake. Choosing the best cyclotide framework ought
to be dependent upon the cells to be targeted, the cargo, and
the location of its target in the cell. For instance, MCoTI-II seems
to be internalized by multiple endocytic pathways, but in partic-
ular by macropinocytosis (Cascales et al., 2011). We are unsure
whether and how MCoTI-I/II peptides escape endosomes, but
the fact that this peptide when grafted with a functional segment
of p53 can inhibit the interaction of the oncogenic protein HdmX
with p53, both located in the cytoplasm, suggests that the
grafted peptide and/or an active metabolite is also active in the
cytoplasm (Ji et al., 2013). kB1 seems to be able to target PE-
rich membranes and to enter through endocytosis, but also to
translocate through the plasma membrane in a soluble form.
Therefore, kB1 presents itself as a good choice of scaffold for
grafting of bioactive sequences that bind endosomal, mem-
brane-bound, or soluble targets. Furthermore, as cancer cells
typically contain a higher proportion of exposed PE phospho-
lipids than healthy cells, kB1 might also be a useful scaffold for
targeting cancer cells, and could enable inhibition of a specific
cell type when equipped with a specific bioactive epitope.
SIGNIFICANCE
Intracellular protein-protein interactions have emerged as
therapeutic targets but have been considered as ‘‘undrug-
gable.’’ Typically, protein-protein interactions involve large
surface areas difficult to modulate by traditional small-
molecule drugs and inaccessible to large biologics unable
to internalize inside cells. Cyclotides are peptides withsevier Ltd All rights reserved
exceptional stability, ability to cross cell membranes, and
‘‘plasticity’’ to be engineered. Accordingly, they have gener-
ated much interest as next-generation drug scaffolds with
the ability to enter cells and also to be engineered to inhibit
intracellular drug targets that are out of reach of conven-
tional drugs. Prior to the development and broad application
of these potential drug scaffolds, it is important to under-
stand their mode of action. Here we characterize how kalata
B1, the prototypic cyclotide, crosses the cell membrane bar-
rier. This information can be applied in tailoring engineered
cyclotides for specific intracellular targets, and in the devel-
opment of drug-discovery programs for the development of
stable delivery systems.
EXPERIMENTAL PROCEDURES
Additional details on the experimental procedures are provided in the Supple-
mental Information.
Peptide Extraction and Synthesis
Native kB1 was isolated from Oldenlandia affinis (Plan et al., 2007), and Lys
mutants of kB1 were synthesized and purified as described previously (Huang
et al., 2010). The linear peptides were synthesized using an automated pep-
tide synthesizer (Symphony peptide synthesizer, Protein Technologies) as
described previously (D’Souza et al., 2014).
Peptide Labeling
Single Lys peptides were labeled with Alexa Fluor 488 sulfodichlorophenol
ester or pHrodo green sulfotetrafluorophenyl ester (Life Technologies) through
amide-bound ligation (Torcato et al., 2013).
Internalization of kB1 into Cells Followed by Flow Cytometry
Internalization of labeled peptides was evaluated using a BD FACSCanto II
flow cytometer, as described previously (D’Souza et al., 2014; Torcato et al.,
2013).
Internalization Followed by Confocal Microscopy
HeLa cells were incubated with T20K*, V25K*, T16K*, or T20K-pHrodo and
imaged at 37C using an inverted LSM 710 confocal laser scanning micro-
scope (Zeiss) equipped with a cage with temperature control.
Internalization Followed by Mass Spectrometry
HeLa cells were incubated with kB1 for 1 hr at 37C. To distinguish between
membrane-bound and soluble peptide, cells were disrupted and cell debris
separated from supernatant. To estimate the amount of peptide associated
with the ‘‘whole cell,’’ cell debris was not separated from supernatant. A stan-
dard curve was prepared by solubilizing peptide stocks in PBS. A linear aceto-
nitrile gradient was used to separate sample components on a Phenomenex
Kinetex C18 column (100 3 2.1 mm, 1.7 mm particle size, 100 A˚ pore size) at
a flow rate of 0.4 ml min1, and analyte MRMsmonitored using a 4000 QTRAP
tandem mass spectrometry system (AB/Sciex, Foster City, USA). The peptide
concentration in each sample was calculated based on the standard curve.
Preparation of Liposomes by Extrusion
Synthetic lipids (POPC, DPPC, DMPC, DMPE, DOPC, DOPE, 1-palmitoyl-2(6-
nitrobenzoxadiazole-aminocaproyl)-glycerophosphocholine, and 1-palmitoyl-
2(6-nitrobenzoxadiazole-aminocaproyl)-glycerophosphoethanolamine [NBD-
PE]) were obtained from Avanti Polar Lipids. Unless otherwise stated, vesicle
suspensions were prepared in 10 mM HEPES buffer (pH 7.4) containing
150 mM NaCl, and small unilamellar vesicles (50 nm diameter) were prepared
by freeze-thaw fracturing and sized by extrusion following protocols previously
optimized (Henriques et al., 2008).
Peptide-Membrane Interactions Followed by SPR
Unless otherwise stated, SPR experiments were conducted at 25Cwith an L1
biosensor chip in a Biacore 3000 instrument (GE Healthcare) and using 10 mMChemistry & Biology 22, 1087–HEPES buffer (pH 7.4) containing 150 mM NaCl as running buffer. Peptides
were injected over bilayers deposited onto the chip at 25C and response units
normalized to P/L as previously detailed (Henriques et al., 2011, 2012).
Preparation of GVs and Imaging by Confocal Microscopy
GVs labeled with 1% NBD-PE were prepared in 200 mM sucrose solution by
electroformation using indium tin oxide-coated glass slides (surface resistivity
30–60 U, Sigma). GV suspensions were excited at 488 nm and images re-
corded upon addition of kB1 or T16K (5 or 10 mM) using an inverted LSM
510 confocal laser scanning microscope (Zeiss).
Solid-State NMR Experiments
Multilamellar vesicles in the presence or absence of kB1 (peptide/lipid molar
ratio 10:1) were resuspended with Tris buffer (30 mM Tris [pH 7.4], 100 mM
NaCl) to 75% hydration and packed into a 5-mm rotor. 2H NMR experiments
were performed on a Varian Inova 300-MHz spectrometer using a 5-mm Auto-
MAS double resonance probe (Varian), and spectra were collected as
described previously (Weber et al., 2012). Proton-decoupled 31P NMR spectra
were collected at 242.5MHz resonance frequency using a 4.5-msp/2 pulse, 3 s
recycle delay, 125 kHz spectral width, and a SPINAL decoupling scheme.MAS
31P experiments were performed at 10-kHz spinning speed with an acquisition
time of 20 ms using a SPINAL-64 decoupling scheme of 48 kHz strength and a
minimum of 512 scans.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.07.012.
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